SkQ1
Mitochondria-Targeted Research Compoundprescription
SkQ1 is a plastoquinone-containing mitochondria-targeted compound clinically studied as an eye drop. Other routes are experimental and must not inherit ophthalmic evidence.
Pharmacokinetic model
A route-level PK model for skq1 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Mitochondria-Targeted Research Compound
- Suggested cadence
- once daily
Research behind this entry
-
SkQ1 Ophthalmic Solution for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study
Ninety-one participants with dry eye used 0.155 or 1.55 mcg/mL SkQ1 ophthalmic solution or placebo for 29 days. The study was local and did not report systemic pharmacokinetics.
1 published study referenced in the app, each with a plain-language summary.